Table 2.

Clinical features and laboratory findings before and after treatment

		Before	After 14 weeks		After 30 weeks		Interaction	Variation between individuals	Intraindividual variability
	Group		Value	p*	Value	P**	p***	p***	p***
SDS	Infliximab	44.8±10.9	37.1±9.4	<0.001	37.9±10.7	<0.001	0.086	0.006	0.001
	MTX	44.0±9.9	40.7±11.0	0.022	39.7±10.4	0.002
DAS28 (ESR4)	Infliximab	5.53±1.31	3.99±1.48	<0.001	3.93±1.52	<0.001	0.98	0.199	<0.001
	MTX	5.22±0.93	3.64±1.00	<0.001	3.61±1.31	<0.001
mHAQ	Infliximab	0.70±0.66	0.40±0.41	0.002	0.39±0.49	0.008	0.94	0.33	<0.001
	MTX	0.60±0.56	0.33±0.45	0.004	0.28±0.48	<0.001

mean±SD

^*Compared with before treatment

^**Compared with before treatment

^***Analysis by repeated-measures ANOVA